GlobeNewswire by notified

Transforming Cancer Care: Novotech Releases Report on Radiopharmaceuticals Global Clinical Trials Landscape


BOSTON, June 26, 2024 (GLOBE NEWSWIRE) -- Novotech, an internationally renowned full-service clinical Contract Research Organization (CRO) known for its collaboration with biotech firms to accelerate the development of innovative therapeutics across all phases, has today published a leading industry report, Radiopharmaceuticals - Global Clinical Trial Landscape.

Over the past 25 years cancer treatment has evolved significantly, incorporating advanced therapies such as target treatments and immunotherapies alongside traditional methods like surgery and chemotherapy. Recently, the development of radiopharmaceuticals - targeted radiation therapy - has marked a significant innovation in treatment, delivering radiation directly to cancer cells, and minimizing damage to healthy tissue.

This expert report, provided by the Novotech research analyst team free of charge, highlights a promising new direction in oncology care. The report delves into the evolving landscape of radiopharmaceuticals including innovations, approval processes, the funding landscape and opportunities and considerations for this treatment in future.

The report shows the global clinical trial landscape for radiopharmaceuticals has seen substantial growth. Between 2019 and 2024, the sector experienced a 24.57% annual growth rate in unique trials, with 150 ongoing industry-initiated trials. North America leads this effort, contributing 42% of the global trials, followed by the Asia-Pacific region (28%) and Europe (26%). The United States is the foremost contributor, accounting for 79% of North America's trials. Significant activity is also seen in other regions including Australia, China, and France.

Radiopharmaceutical trials have predominantly focused on oncology with the top indications being prostate, neuroendocrine, central nervous system (CNS), gastrointestinal tract, and lung cancers. The regional distribution of trials by phase showed North America leading in single-country Phase I and II trials, while Europe exceeded Asia-Pacific in multinational trials across all phases.

In terms of patient recruitment, the landscape reflected similar enrollment periods across regions, however, the United States led in recruitment efficiency with 0.34 subjects per site per month, likely due to its advanced infrastructure and streamlined regulatory processes.

Key takeaways from the report:

  • The radiopharmaceuticals market is expected to grow significantly, with a projected compound annual growth rate (CAGR) of 8.4% from 2021 to 2028. The global radiopharmaceuticals market was valued at $4.8 billion in 2020 and is anticipated to reach $9.6 billion by 2028.
  • Oncology remains the dominant therapeutic area, representing approximately 60% of all radiopharmaceutical clinical trials, followed by cardiology and neurology.
  • Recent years have seen an increase in radiopharmaceuticals receiving regulatory approval, indicating a positive trend in the development pipeline.
  • Major players in the radiopharmaceuticals sector include Novartis, GE Healthcare, and Cardinal Health, who lead the way in both market share and innovation.
  • Asia-Pacific is emerging as a significant region for radiopharmaceutical clinical trials, with countries like China and India showing increased activity and investment.
  • Advances in imaging technologies, such as PET and SPECT, are driving the development and application of new radiopharmaceuticals, enhancing diagnostic accuracy and treatment efficacy.
  • Venture capital and private equity investment in radiopharmaceutical companies have surged, with over US$1 billion invested in the last year alone, reflecting growing confidence in this sector's potential.

This comprehensive radiopharmaceuticals report is a resource to guide healthcare professionals, researchers, and organisations in navigating the global trial landscape.

Download the report here


Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit

A photo accompanying this announcement is available at

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

HiddenA line styled icon from Orion Icon Library.Eye